This week in Drug Discovery (13 – 17 July)
News round-up for 13 – 17 July by Bruno Quinney, Content Team at DDW.
This week, a new drug has shown potential to treat heart disease. Elsewhere, Cancer Research UK is leading a global cancer trial.
The top stories:
New drug could treat common heart disease, study shows
The TEMPEST trial, led by researchers at the University of Manchester, tested the drug trientine in 154 adults with hypertrophic cardiomyopathy in a year-long, placebo-controlled study.
mRNA technology could treat autoimmune diseases, study shows
Scientists at the Biomedical Research Institute (BIOMED) at Hasselt University and the Belgian biotech company etherna have demonstrated that mRNA technology, which gained recognition for its use in Covid-19 vaccines, also holds promise for the targeted treatment of autoimmune diseases.
Study proves preclinical efficacy of gene therapy for metabolic disorder
Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has revealed preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy approach to treat metabolic disorder methylmalonic acidemia (MMA).
Cancer Research UK leads global trial of rare cancer therapy
Biotechnology company Cytovation and the Norwegian Cancer Society (NCS) have joined forces with Cancer Research UK for the trial of people with advanced adrenocortical carcinoma (ACC), a rare and aggressive cancer.
National programme to support data-driven health start-ups
KQ Labs, led by the Francis Crick Institute and Medicines Discovery Catapult (MDC), is an annual five-month programme for early-stage companies building science-backed, scalable solutions in AI-driven drug discovery, digital health, and precision medicine.
Chris Molloy, BIA, keynotes Drug Discovery Innovators & Investors, UK Conference
We’re delighted to announce Chris Molloy, Chief Executive Officer of the UK BioIndustry Association (BIA), as keynote speaker at Drug Discovery Innovators & Investors, London, UK Conference.
